The effect of fasting plasma glucose variability on the risk of retinopathy in type 2 diabetic patients: Retrospective long-term follow-up

Diabetes Research and Clinical Practice

Volumn 89, Issue 3, 2010, Pages 296-302

  Takao, Toshiko ^a   Ide, Takehiko ^a   Yanagisawa, Hiroyuki ^b   Kikuchi, Masatoshi ^a   Kawazu, Shoji ^a   Matsuyama, Yutaka ^c  

^a INSTITUTE FOR ADULT DISEASES   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Fasting plasma glucose variability; Glycemic control; Long term follow up; Retinopathy; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C;

ADULT; AGED; ARTICLE; DIABETIC RETINOPATHY; DIET RESTRICTION; DISEASE COURSE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

EID: 77955423064     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.03.027     Document Type: Article

References (21)

1. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993, 329:977-986.
2. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
3. Ohkubo Y., Kishikawa H., Araki E., Miyata T., Isami S., Motoyoshi S., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res. Clin. Pract. 1995, 28:103-117.
4. McCall A.L., Kovatchev B.P. The median is not the only message: a clinician's perspective on mathematical analysis of glycemic variability and modeling in diabetes mellitus. J. Diabetes Sci. Technol. 2009, 3(1):3-11.
5. DECODE Study Group Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch. Intern. Med. 2001, 161(3):397-405.
6. Nakagami T., Qiao Q., Tuomilehto J., Balkau B., Tajima N., Hu G., et al. Screen-detected diabetes, hypertention and hyperchoresterolemia as predictors origin: the DECODA study. Eur. J. Cardiovasc. Prev. Rehabil. 2006, 13(4):555-561.
7. Levitan E.B., Song Y., Ford E.S., Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch. Intern. Med. 2004, 164(19):2147-2155.
8. Cavalot F., Petrelli A., Traversa M., Bonomo K., Fiora E., Conti M., et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J. Clin. Endocrinol. Metab. 2006, 91(3):813-819.
9. Barrett-Connor E., Ferrara A. Isolated postchallenge hyperglycemia and the risk of fetal cardiovascular disease in older women and men. The Rancho Bernardo Study. Diabetes Care 1998, 21:1236-1239.
10. Siraiwa T., Kaneto H., Miyatsuka T., Kato K., Yamamoto K., Kawashima A., et al. Post-prandial hyperglycemia is an important predictor of the incidence of diabetic microangiopathy in Japanese type 2 diabetic patients. Biochem. Biophys. Res. Commun. 2005, 336(1):339-345.
11. Shichiri M., Kishikawa H., Ohkubo Y., Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000, 23(Suppl. 2):B20-29.
12. Muggeo M., Zoppini G., Bonora E., Brun E., Bonadonna R.C., Moghetti P., et al. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients The Verona Diabetes Study. Diabetes Care 2000, 23(1):45-50.
13. Hirsch I.B., Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control?. J. Diabetes Comp. 2005, 19(3):178-181.
14. Lachin J.M., Genuth S., Nathan D.M., Zinman B., Rutledge B.N. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial-revisited. Diabetes 2008, 57(4):995-1001. DCCT/EDIC Research Group.
15. Gimeno-Orna J.A., Castro-Alonso F.J., Boned-Juliani B., Lou-Arnal L.M. Fasting plasma glucose variability as a risk factor of retinopathy in type 2 diabetic patients. Diabetes Comp. 2003, 17:78-81.
16. Zoppini G., Verlato G., Targher G., Casati S., Gusson E., Biasi V., et al. Is fasting glucose variability a risk factor for retinopathy in people with type 2 diabetes?. Nutr. Metab. Cardiovasc. Dis. 2009, 19(5):334-339.
17. Kilpatrick E.S., Rigby A.S., Atkin S.L. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2006, 29(7):1486-1490.
18. Kilpatrick E.S., Rigby A.S., Atkin S.L. The effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes. Diabetes Care 2009, 32(10):1901-1903.
19. Service F.J., O'Brien P.C. The relation of glycaemia to the risk of development and progression of retinopathy in the Diabetic Control and Complications Trial. Diabetologia 2001, 44:1215-1220.
20. Bragd J., Adamson U., Bäcklund L.B., Lins P.E., Moberg E., Oskarsson P. Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade?. Diabetes Metab. 2008, 34:612-616.
21. Kilpatrick E.S, Rigby A.S., Atkin S.L. A1C variability and the risk of microvascular complications in type 1 diabetes. Diabetes Care 2008, 31(11):2198-2202.